Press Releases
Feb 1, 2017
Summary ToggleIntellia Therapeutics to Present at Leerink Partners 6th Annual Global Healthcare Conference
CAMBRIDGE, Mass. , Feb. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Executive Officer and Founder Nessan Bermingham ,
Jan 11, 2017
Summary ToggleIntellia Therapeutics Joins Genomics England’s Industry Consortium
CAMBRIDGE, Mass. and LONDON, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics (NASDAQ:NTLA) has joined the Genomics England Genomics Expert Network for Enterprises (GENE) Consortium , as the first, dedicated genome editing company to participate in the 100,000 Genomes Project .
Dec 16, 2016
Summary ToggleCRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology
BASEL, Switzerland, CAMBRIDGE, Mass., BERKELEY, California, DUBLIN, Ireland, December 16, 2016 (GLOBE NEWSWIRE) – CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics (NASDAQ:NTLA), Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered
Dec 13, 2016
Summary ToggleIntellia Therapeutics Names Graeme Bell Chief Financial Officer
CAMBRIDGE, Mass. , Dec. 13, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9 technology, has appointed Graeme Bell as its Chief Financial Officer. Mr.
Dec 1, 2016
Summary ToggleIntellia Therapeutics Opens New Headquarters as Company Continues to Advance CRISPR/Cas9 Platform and Pipeline
- Positions Intellia for R&D growth and progress toward clinical studies - - Accommodates hiring plans to support pipeline of CRISPR/Cas9 based therapeutics - CAMBRIDGE, Mass. , Dec. 01, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused
Nov 1, 2016
Summary ToggleIntellia Therapeutics Reports Financial Results for Third Quarter 2016
First company to report high in vivo editing data using CRISPR/Cas9 in animal models Further validation of lipid nanoparticle delivery platform Ended quarter with $290.6 million in cash and cash equivalents CAMBRIDGE, Mass. , Nov. 01, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Oct 31, 2016
Summary ToggleIntellia Therapeutics to Present at November Investor Healthcare Conferences
CAMBRIDGE, Mass. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that senior company leaders will present at key November investor
Oct 14, 2016
Summary ToggleIntellia Therapeutics to Present Data at the European Society of Gene & Cell Therapy Congress
CAMBRIDGE, Mass. , Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that members of its scientific team will present new data at the
Oct 5, 2016
Summary ToggleIntellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit
CAMBRIDGE, Mass. , Oct. 05, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Medical Officer John Leonard , M.D., will participate
Sep 1, 2016
Summary ToggleIntellia Therapeutics to Present at September Investor Healthcare Conferences
CAMBRIDGE, Mass. , Sept. 01, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that CEO and Founder Nessan Bermingham , Ph.D., will present at
